Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

225
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
225
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

186
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
186
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

296
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
296
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

410
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
410
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

297
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
297

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Environmental Microbiomes, Resistomes and Plasmidomes from a Human Tertiary Hospital and Companion Animal Veterinary Hospital in London, UK.

Antibiotics (Basel, Switzerland)·2026
Same author

Within-household transmission risk of pulmonary tuberculosis in the era of universal antiretroviral therapy.

medRxiv : the preprint server for health sciences·2026
Same author

Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatment.

Nature communications·2026
Same author

Neglected tropical diseases in conflict zones: devastating consequences of a lack of inclusion.

International health·2026
Same author

Evaluation of Xpert MTB/XDR and Deeplex Myc-TB for the Rapid Detection of Drug Resistance in <i>Mycobacterium tuberculosis</i>.

International journal of microbiology·2026
Same author

Population pharmacokinetics and target attainment of pretomanid in rifampicin-resistant tuberculosis patients.

Scientific reports·2026

Related Experiment Video

Updated: Aug 16, 2025

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.

Bern-Thomas Nyang'wa1, Catherine Berry1, Emil Kazounis1

  • 1From the Public Health Department, Operational Center Amsterdam (OCA), Médecins sans Frontières, Amsterdam (B.-T.N., K.R.); the Public Health Department, OCA, Médecins sans Frontières (C.B., E.K., I.M.), the London School of Hygiene and Tropical Medicine (B.-T.N., M.D., D.A.J.M., K.F.), and University College London (T.D.M.) - all in London; the Republican Specialized Scientific and Practical Medical Center of Phthisiology and Pulmonology, Tashkent (N.P., I.L.), and the Republican Phthisiological Hospital No. 2, Nukus (Z.T.) - both in Uzbekistan; the Republican Scientific and Practical Center for Pulmonology and Tuberculosis, Minsk, Belarus (V.S.); THINK TB and HIV Investigative Network, Durban (R.M.), and Wits Health Consortium, Johannesburg (N.N., M.R.) - both in South Africa; the Global Alliance for TB Drug Development, New York (M.S.); and the Burnet Institute, Melbourne, VIC, Australia (P.C.).

The New England Journal of Medicine
|December 22, 2022
PubMed
Summary

A new all-oral tuberculosis treatment regimen (BPaLM) proved noninferior to standard care. This shorter, 24-week regimen offers a better safety profile for rifampin-resistant tuberculosis.

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K

Related Experiment Videos

Last Updated: Aug 16, 2025

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K

Area of Science:

  • Infectious Diseases
  • Clinical Trials
  • Pharmacology

Background:

  • Rifampin-resistant tuberculosis requires more effective, shorter, and safer treatment options.
  • Current treatment regimens for multidrug-resistant tuberculosis are lengthy and associated with significant side effects.

Purpose of the Study:

  • To evaluate the efficacy and safety of a novel 24-week, all-oral regimen for rifampin-resistant tuberculosis.
  • To compare the BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) against standard-care treatment.

Main Methods:

  • An open-label, phase 2-3, multicenter, randomized, controlled, noninferiority trial was conducted.
  • Patients with rifampin-resistant pulmonary tuberculosis received either the 24-week BPaLM regimen or a 9-to-20-month standard-care regimen.
  • The primary outcome was unfavorable status at 72 weeks post-randomization.

Main Results:

  • The BPaLM regimen demonstrated noninferiority to standard care in the modified intention-to-treat analysis (11% vs. 48% unfavorable status).
  • Per-protocol analysis showed a lower incidence of unfavorable outcomes with BPaLM (4% vs. 12%).
  • The BPaLM group experienced significantly fewer severe adverse events (19% vs. 59%).

Conclusions:

  • A 24-week, all-oral regimen (BPaLM) is noninferior to standard-care treatment for rifampin-resistant pulmonary tuberculosis.
  • The BPaLM regimen offers a significantly improved safety profile compared to standard care.
  • This study supports the use of shorter, all-oral regimens for treating resistant tuberculosis.